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ABSTRACT Research in genomics is an example of changes induced by information and
communication technologies (ICT). The emergence of interconnected ICT support for scientific
work and the handling of information have changed the challenges in genomics as well as other
scientific fields. The promises are significant but a large degree of uncertainty remains. While
the information space is opened up, R&D cooperation essential to reaping the benefits for
companies is still difficult. Moreover, in order to benefit in full from the possibility to combine
knowledge on a larger scale, knowledge repositories and places of knowledge creation need to be
combined. This paper discusses the new strategies of information networking between companies
that emerges in response to this challenge. It concludes with an outline of a research agenda for
genomics and society.
Introduction
The use of information and communication technologies (ICT) has a broad
impact on research practices in a variety of laboratory and experimental settings
(National Research Council, 1997; OECD, 1999). This has pervasive effects on
different levels of activity in scientific research and discovery, from discovery
itself in laboratory research, the exploitation of research findings in R&D
projects, to strategies in intercorporate alliances. Internet-based communication
has proliferated and provided the means for engaging in new knowledge
creating—interactions among researchers at the level of the research project as
well as at the level of institutions and international collaborative arrangements
(Buisseret & Cameron, 1994; Kru¨ck, 1995; Powell et al., 1996; Zucker et al.,
1996). These new developments require knowledge-intensive companies, re-
search organizations, and research facilities to have permanent access to compu-
tational capabilities and research communication networks. ICT plays a crucial
role in acquiring and maintaining this access.
It is not yet entirely clear to what extent ICT have transformed actual
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practices of pharmaceuticals and biotechnology companies. The role of ICT is
in this field intertwined with the emergence of the increased pace of genetic
research. Four years ago, Enriquez and Goldberg (2000) claimed that the
experience of large companies such as Monsanto and Dupont shows that the
genetic revolution has created new sector conditions. Their crucial argument is
that a new science-driven dynamic has been created that forces companies to
follow the flow:
As scientific advances accelerate, more and more companies will be
drawn, by choice or necessity, into the life-science business. They, too,
will confront challenges unlike any they’ve faced before. And the way
they meet those challenges will not just determine their commercial
success; it will also have a direct influence over the future of life on our
planet. (Enriquez & Goldberg, 2000, p. 97)
This paper appeared at the high point of optimism about the consequences of
ICT applications and biotechnology in the pharmaceutical industry. Two cru-
cial developments seemed to open up fundamentally new opportunities. First,
the emergence of e-commerce carried by the internet seemed to enable new
marketing strategies and business to business (B2B) communications. Second,
the unravelling of the human genetic code seemed to have created a new era in
which medical drugs, diagnostics, and therapeutics might be based on detailed
knowledge of the underlying molecular mechanisms in the human body. Since
then, however, rampant optimism has given way to more sobering thoughts. In
a sense some of the technical promises mentioned above can be analysed as part
of the engineering culture of promises (Van Lente & Rip, 1998). The large
companies discussed by Enriquez and Goldberg have since 2000 shed some of
the activities mentioned, such as their pharmaceutical divisions. They concen-
trate on more mundane chemical markets with their ‘old fashioned’ core
technologies. Nevertheless, it is the pharmaceutical industry that shows the
vicissitudes of the new conditions for knowledge production. The need to
increase the variety of interesting products in the pipeline for pharmaceutical
purposes and to garner new markets has spurred many cooperative projects in
the search phase of drug discovery as well as increased investment in ICT.
The new innovative organization of knowledge-based production has been
called the next phase after the Fordism-based standardization and mass cus-
tomisation (Miles et al., 2000). In part this reconfiguration can be developed
within the existing organizations. However, in large part the formation of
networks and the interconnection with public research is a necessary condition
for innovative organizations (Freeman, 1991). The changes induced by inter-
national collaboration have had a marked effect on the global organisation of
science and technology. In recent OECD reports, the claim is made that an
important transformation of the research system is occurring. Both inward and
outward research-related foreign investment has become more important. The
explosion of international strategic alliances is another indicator (OECD, 1999a).
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
5:
42
 3
1 
Ma
y 
20
11
Genomics, ICT and the formation of R&D networks 169
Interorganisational collaboration has interesting aspects with regards to knowl-
edge creation, dissemination and use. These collaborations are not necessarily
ICT bound. Co-operation has been described in different innovation studies
on the interaction between companies and between companies and public
sector research. One of the assumptions is that the industrial R&D needs
direct experience and input from university and government research
scientists (Faulkner et al., 1995). These public-private co-operations therefore
serve in part as knowledge conduits. In this paper, we concentrate on the
relationships between the use of ICT in genomics research, the R&D process
and pharmaceutical R&D. This field is interesting because it is a crucial area
where the support of knowledge creation by ICT should have benefits (Howells,
2002).
The effects of ICT are discernible in the field of genomics at three levels: the
level of laboratory practices, the level of research communication and inter-
group collaboration, and the level of institutional networks. In this paper
we highlight a number of the changes induced by ICT use, that might have
significant impacts on the complex interactions between the research field
of genetics and the commercial exploitation of science in firms, and more
generally on the relationship between science and society. Our first step is a
discussion of the manner in which the production and use of scientific knowl-
edge in genomics is changing R&D. We see genomics as characterized by
the merging of information technology and genetics, each with its own dynam-
ics. We discuss how this interaction leads to a process of informatisation of
research practices (Webster, 1995; Castells, 1996). Second, we discuss how the
application of ICT in communication and the creation of large, distributed
databases have induced a new organisation of the management of information
flows in the R&D process. This development has created a new discovery
environment in genomics, conceptualised as a socio-technical system character-
ised by intense interactions among human actors (scientists and technicians)
and ICT (de Jong & Rip, 1997). Third, we explore how the increasing use of
communication platforms is leading to the interweaving and interlocking of
a variety of different hitherto separated economic actors. The field of interacting
organizations itself is still in constant flux. We regard the network that
is emerging as a temporal constellation. The interaction between the field
level and the two underlying levels (laboratory and collaboration) is character-
ised by uncertainties and complex feedback processes (Orsenigo et al., 2001).
The paper concludes with a research agenda of these interactions that addresses
the encompassing nature of the changes, possible future outcomes and some of
the social issues that may arise from these developments. This research agenda
focuses on the process of mediation of these institutional interactions, which has
so far not yet been addressed in a systematic way in the literature on innovation.
In the following sections, we will detail the aspects of this layered network of
workbench, R&D integration and company networking for the case of drug
development.
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The informational turn in research practices
The development of genetics as a scientific and technical field has been deeply
influenced by an increased role of computing and electronic communication.
ICT have become crucial in various phases of the discovery process. The
development of the field of bioinformatics is the direct consequence of this. In
the first stage of the introduction of computing into biological sciences in the
1970s and 1980s, computer modelling and AI were introduced into biochem-
istry (Lenoir, 1999). Earlier on, other areas of biology such as taxonomy
introduced computers because of which a gradual transformation of research
work took place (Hagen, 2001). For instance, the introduction of computers as
tools for repetitious tasks in taxonomy ‘forced taxonomists to make their
methods explicit, but just as importantly the machines served as icons of
objectivity’ (Hagen, 2001, p. 310). In the second stage of the widespread use of
ICT, new information techniques supported the requirements of increased data
management and database organisation. Both have led to the emergence of
bioinformatics as a specific subdiscipline in the 1980s (Lenoir, 1999).
In what manner does ICT affect research work in the laboratory? In the
chemical laboratory new substances can be ‘assembled’ on the basis of an
integration of micro synthesis and information software tools. The emergence of
combinatorial chemistry and high-through-put screening has increased the
‘decision-load’ of researchers. To support their decision-making capability, new
tools have been developed. An example is the development of virtual compound
libraries containing representations of all the molecules that might be easily
obtained by the combinatorial chemistry tricks an R&D laboratory possesses
(Cramer et al., 1998). The use of computers has had an increasing impact on
the development of research bench work in other scientific fields as well. This
process has been characterised as a process of informatisation (Webster, 1995;
Castells, 1996). Due to their generic aspects, the use of ICT by researchers and
scholars is affecting the very core of knowledge practices across the board of all
natural, technical, social and human sciences. The extent, shape and impact of
these changes vary considerably, however, by scientific specialties (Kling &
McKim, 2000). The generic changes in research can best be captured by the
notion of the informational turn (Wouters et al., 2002a; Beaulieu, 2004). First,
digital information and data are playing an increasingly important role in a
variety of research fields (Wouters & Schro¨der, 2000; Wouters et al., 2002b).
This has triggered a number of fields, notably the life sciences, to at least partly
take on the features of data-rich information sciences (Lenoir, 1999). Second,
networked research practices are becoming more abundant, although this
should not be seen as diminishing the importance of local communities (Olson
et al., 2000; Finholt, 2002). In a number of fields, e.g., genomics, nanotechnol-
ogy, and pharmaceutics, these networks link up actors from the academic as well
industrial sectors of society. They are more hybrid than networks which consist
solely of university-based actors.
In genetics, the developments in the first stage of computer applications have
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been stimulated by the sizeable investment by government agencies both in the
US and Europe (Cook-Deegan, 1995). The first development relevant to our
argument concerns the early characteristics of DNA sequencing research as
conceived by the Human Genome Project (Jones, 2000). Technical innovations
played an important role in the process. In order to complete the genetic code
of human DNA large amounts of data were collected. Outcomes of sequencing
needed to be stored, communicated, and combined, the data handling score
became an important bottleneck. This was the basis of the first bioinformatics
effort, i.e., the application of ICT to problems of biology. It also provided a first
niche for scientific entrepreneurs to exploit. The support activities in gene
discovery require access to information on sequences and function of genetic
material. This has been organised by various public and commercial laborato-
ries. Examples of universities starting with a service model for accessing gene
information are Oxford, Stanford, and Sydney.
One of the interesting aspects of these new developments is that they occur
in incremental steps. Each step seems to reinforce a digitisation/informatisation
cycle, also leading to intervention from a higher level of organisation.
An increasing number of chemical problems can be solved through the
calculation of key processes and structures, thus enabling the definition of new
substances on the basis of theoretical insights (Wilson, 2000). In computational
chemistry, desktop visualization of chemical activity information has expanded
the possibilities of combining mathematical theoretical constructs and the
chemical engineering of new substances. This requires significant computing
power for interactive 3D structure visualization (Krieger, 1996). The visualisa-
tion has an important role in two different respects. First, it allows for a more
intuitive use of information including structural aspects of molecules and will
allow for manipulation of visualisation models. Second, there is an emergence of
information based R&D integrating public information sources, organizational
processes and research into a specialised information environment. This may
mean that the pure information tasks are increasingly combined with the
research process and organisation, through software and web based connections.
Following de Jong and Rip it can be argued that the consequence of such ICT
applications will be the rearrangement of various elements of the context of
discovery (de Jong & Rip, 1997). This has recently been underlined by the
creation of a new ‘robot scientist’ (King et al., 2004) that is more powerful than
the first one created in 1990 (Zytkow et al., 1990). This robot is able to originate
hypotheses to explain observations, devise experiments to test these hypotheses,
physically run the experiments using another robot, interpret the results to
falsify hypotheses inconsistent with the data, and to repeat this cycle.
An important second step in this development has been to link these data into
internet- and web-based systems also encompassing links to suppliers, gene
information, reagents and biological materials. Software development is crucial,
in the creation of both proprietary databases and public sources, such the
Human Genome Project and the SNP consortium (Thayer, 2000). On this
basis, the communication work of the research process is actively integrated with
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the available information from different sources. The companies active in this
area want to tie all relevant processes together into one system: gene discovery,
target screening and selection chemical structure, and synthesis and clinical
studies. The main feature is the design of drugs. Last, the various data are being
integrated into one overall research and design environment, in which visualiza-
tion tools are playing an important role. This is an indication of the networking
basis that is established. A subsequent step has been the active integration of the
management aspects of the research process with the available information from
different sources. The service companies active in this area want to tie ERP-type
systems together into one system gene discovery, target screening, selection of
chemical structure and synthesis, and clinical studies. How does this emerging
practice shape the conditions for corporate strategies and cooperations?
ICT, communication and collaboration in R&D: managing the new
discovery environments
Much of the developments described in the previous section are an indication
of the virtualisation of the organisational information infrastructure. One promi-
nent question that arises concerns the consequences of these changes for the
work processes in R&D. Thus study of communication in R&D as a social
process is relevant to the distributed character of knowledge production. Allen
(1977) studied information and communication patterns in corporate R&D
concentrating on communication between researchers in one location. He found
that members of research groups play different social roles in the communi-
cation of knowledge. Gatekeepers, not necessarily the workgroup leader, played
a central role in gathering diverse information for research. They influenced
what others considered reputable and relevant knowledge. Researchers who take
the role of communication gatekeepers regulated access strategic information
(Allen, 1977). In fulfilling this role relations, informal social connections and
physical co-location played an important part in whom would fulfil this role.
Also other research underlined the importance of boundary roles in the social
context of a development teams as important (Tushman, 1977). The relevance
of these processes is evident as the R&D process is increasingly characterized by
heterogeneity of inputs as well as the internationalisation of research work
within the same company (Granstrand et al., 1993; Haour, 1998; Staropoli,
1998; OECD, 1999; Munari et al., 2002). ICT support, exchange via expert
lists, and ICT supported networked co-operation have become increasingly
important:
These [electronic and software] tools can help to get from electronics
the managerial and knowledge value needed to pursue two main
objectives: to use electronic space in a truly managerial way, instead of
using it for the transaction of information bit; to sharpen knowledge
the knowledge and information base of the firm. (Haour, 1998)
While computer supported cooperative work is very much accepted as a feature
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of the current work environment its impact on those organisational processes
that are required for support have received scant attention from information
scientists as well as social scientists.
In early studies it was argued that computer mediated communication
strengthens the position of professional communities across organizational bor-
ders. This trend would increase the tension between corporations that want to
reap the benefits of expertise internally and their knowledge workers (Pickering
& King, 1999). The integration of new ICT tools in R&D increases the need to
coordinate the R&D workflow. It raises the question: ‘What tools can help to
build the frames of reference needed to organize and coordinate intellectual
activity?’ (Bowker et al., 1997, p. xvi). But the reverse is also true: in order to
support cooperation, coordination and through the integration of systems,
coordination of work processes at the level of companies and between organiza-
tions are a prerequisite. The ICT support processes can be distinguished in two
forms: one providing the knowledge repositories for R&D processes (as dis-
cussed in the previous section), the other supporting the communication within
the R&D process itself.
The improvement of communication within R&D is in all probability
influenced along patterns that are similar to those found in the much wider
studied work of teams in product development. Various studies found that the
main enabling factor governing the adequate use of new ICT infrastructure is
establishing working relationships based on personal social contacts. In absence
of such trust building mechanisms, based on traditional organizational and
human relations management, supporting ICT infrastructure is rather ineffec-
tive (Boutellier et al., 1998). In particular the transfer of tacit knowledge is
considered to be essential for the application of breakthrough information.
Hansen studied cooperation in product development in an international com-
pany and found that the characteristics of the social network influenced the use
of technical knowledge. Strong (social, personal friend, cooperative experience)
ties in the interunit network of the company enabled the transfer tacit know how
(Hansen, 1999, 2002).
Already before the emergence of ICT support mechanisms, drug development
has been characterized by a significant degree of outsourcing. The need to
further reduce costs is driving standardization and sub-contracting to contract
research organizations. Cavalla and Gale (1997) report on a case study of a drug
development project. They focused on the networking between different re-
search, development and product organizations. The familiarity of team mem-
bers with the senior project leader was found to be crucial for the integration of
tasks and outcomes of subcontracted studies. The ability to personally interact
at crucial moments to clarify issues and help with the interpretation of results is
deemed necessary for product development. Notwithstanding this clear trend
towards distributed knowledge production, it is still an open question whether
successful integration can be achieved in circumstances where tasks are dis-
tributed geographically and organizationally (Cavalla & Gale, 1997). In a case
study of virtual teams, Lewis concludes that management control and creating
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shared understandings are crucial issues. A ‘flat’ communication structure only
goes well when participants are clear about their role (Lewis, 1998). In other
studies of electronic information exchange it has been found that ‘natural’
structuring of the information environment occurs, with some participants
taking a much more central role in the network than others (Ahuja & Carley,
1999). Thus, while in discussions of new organizational arrangements for
support of virtual research environments, the suggestion of a seamless web is
dominant, the outcomes of various studies suggest that emergence of directive
organizing of information is essential for the realization of product goals.
To sum up, regardless of the availability of informational tools, communi-
cation networks in R&D laboratories will exhibit structural social characteristics.
These structural characteristics—gatekeepers, leadership or hierarchy, affect the
manner in which information gathering and communication technologies may
be relevant to R&D.
Corporate innovation strategies and cooperation
The pharmaceutical industry is one of the most research-intensive sectors.
Research is the cornerstone of the industry and the sector is one of the largest
spenders on R&D. The development of new drugs is composed of a series of
process, some of which are relatively standardized. A clear distinction is made
by some authors between the research part and the development part (Chiesa,
1996). The research part is dominated by the need to search for new active
chemicals. The theoretical and empirical development of pharmacology has
created a situation in which a large variety of combinations of targets and
chemicals can be combined in strategies for drug design (Orsenigo et al., 2001).
The first step is usually the identification and synthesis of chemical compounds
that are considered to be biologically active. Only a small fraction of these
chemical compounds completes the whole trajectory. In this planned system of
discovery, innovation of the search and development process has played an
important role. In this way, the pharmaceutical companies compose a field of
innovation. In the 1980s and 1990s, the change towards more planned ap-
proaches was stimulated through the development of the pharmacology of
receptors, as well as improvements in the laboratory instruments and auto-
mation. The number of technological fields necessary to identify chemicals for
product development in the pharmaceutical industry is increasing at a rapid
pace. The investment in new drug development is increasingly costly (Gam-
bardella, 1995; Achilladelis & Antonakis, 2001). On the one hand these
developments have driven a process of rapid consolidation (Heracleous &
Murray, 2001). On the other hand it also led to an increase in research alliances
with academia and the emergence of new research companies (Cockburn &
Henderson, 1998; Orsenigo et al., 2001). Orsenigo and co-authors have argued
that the networking activity of the pharmaceutical industry is dependent on
subsequent ‘waves’ of new technologies being absorbed by incumbent firms.
Different waves of collaboration around drug discovery distinguish subsequent
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phases; for instance recombinant DNA, Monoclonal Antibodies, Rational Drug
Design, Oligonucleotides, Combinatorial Chemistry have been traced. R&D
cooperation of large companies focuses on new biotechnology companies,
hospitals and university laboratories (Orsenigo et al., 2001). New biotechnology
firms have formed alliances with large pharmaceutical companies (Kenney,
1986; Grabowski & Vernon, 1994; Shan et al., 1994; Powell, 1998). The
emergence of high throughput screening has led towards more information and
the need to select compounds within a shorter timeframe. Considerable uncer-
tainty in the discovery process is a consequence of this change. This develop-
ment was recognized by senior management but it took considerable time to
overcome the internal resistance to a different manner of workbench decision
making (Thomke & Kuemmerle, 2002). The identification of targets became
one of the steps that were increasingly contracted out to emergent firms. In such
contracts, discovery targets are set by the sponsoring pharmaceutical company
that may lead to significant financial rewards for emergent firms if they reach the
specified milestones. It thus seems that compared to an earlier period the social
network of contracting parties itself has changed, the discovery process has
become more distributed. This trend can be derived from the manner in which
pharmaceutical laboratories have coped with genomics. They extended the
external networking that had already started with the advent of biotechnology.
In addition to the more traditional chemical and biotechnology collaborations,
all kinds of information, software and information technology companies have
become network cooperation parties. The broad screening programs in which
many chemicals were tested on target animals or tissues, could, combined with
microchips on the bench, get more refined with the help of computers in the
laboratory. Examples are the labs-on-a-chip (OECD, 1999, p. 49). It is clear
that the potential for digitised information exchange between various parties is
increasing. Thus the pharmaceutical industry can provide a fruitful example of
how genomics is regarded as an opportunity for gene-based rational drug design
and the use of ICT to facilitate the exchange of relevant information in the R&D
process. The development of new ICT based innovation raises three questions.
First, how is the organization of the innovation process affected by these
changes? Second, who is best positioned to profit from these new opportunities?
Third, what might be the overall consequences of the shifts in the organization
of the innovation process (Miles et al., 2000)?
We consider the genomics sector as an emerging group of firms and other
actors where biotechnology and information technology are being developed for
innovation purposes in the agricultural, health and environmental industries.
The rationalized search for new products based on genetic and additional
biological and health information is increasingly based on the structured sifting
of existing information and the subsequent automatic testing of potential targets
and processes. The core idea of genomics as a business sector, is that increased
digitisation of the discovery process and broader availability of gene and health
databases offers opportunities for new businesses to enter the discovery process.
In the initial phase of the evolution of genomics a lot of optimism existed about
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
5:
42
 3
1 
Ma
y 
20
11
176 Peter Groenewegen & Paul Wouters
TABLE 1. Genomic-related companies’ collaboration and fate
PatentsCollaborations
FateName 1997–2002 Business AreaType 1996–2001
Incyte 622A → C Turned from information11
towards drug development
DoubleTwist dissolved A 7 0 Information provision
Celera 0A → C From data to drug5
development
Millennium D 8 251 Drug development
Affymetrix Sequencing hardware111B 6
CuraGen 20A → C Bioinformatics and drug2
discovery
Genomica acquired 0A Software3
Informax acquired A 2 0 Software
Tripos Software5A 1
Structural SoftwareA 1
Bioinformatics
Spotfire 0 Planning and decision4
making software also outside
pharmaceutical industry
Compugen A 3 0 Software
Lion Bioscience 1reorganized Software tools and targetA 3
identification
Key: (A) information based and software (B) tools for screening (C) screening and targeting
the possibility to find niches in which viable business models based on infor-
mation, information structuring and retrieving functions were seen.
One consequence of this changing environment, is that new organizations and
firms are stimulated to develop new business models for perceived novel
opportunities. A number of ICT and biotechnology-based companies have
emerged that integrate scientific, information and design software with web
applications. The companies that try to profit range from information-based
companies to hardware companies. In Table 1 some of the key issues are
labelled for a set of companies that were identified in trade literature in 2000 as
future key players (Howard, 2000; Reed, 2000). For the data-based companies,
Jones describes the four basic models of information handling these companies
use (Jones, 2000):
• Companies may base themselves on the possession of the tools to collect
large amounts of sequencing information in a minimum of time.
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• Companies that go one step further and combine the sort of data collection
above with preliminary screening of biological targets.
• Other companies add insight in gene functioning to the above.
• Lastly companies emerge that relate gene information to human diseases.
Companies based on models of the exploitation of proprietary scientific and
information advantages adopted a strategy to file patents based on genetic and
protein information, which was made possible in the US. For instance, Human
Genome Sciences has chosen a strategy initially directed at collecting the rights
to large amounts of sequence data. The company Incyte provides another
example in this field. It was founded in 1991 and has functioned as a provider
of proprietary genome databases and analytical tools. Incyte was one of the first
biotech companies to engage in high-throughput computer-aided gene sequenc-
ing for the purpose of identifying genes and their corresponding proteins with
potential therapeutic applications. Incyte’s database discovery approach com-
pares partial human genes or protein sequences to genes or proteins of known
sequence in order to predict their biological or therapeutic function. Prior to
commencing its gene-sequencing program, Incyte used its database discovery
approach to identify specific cell proteins that were expected to have pharma-
ceutical utility. In this way, it aimed at differentiation itself from other infor-
mation providers.
Other new companies have provided commercial access with supportive
software. Examples of these are Doubletwist (US, Stanford related) and eBioin-
formatics (US- Australia). Specialized companies also provide services such as
consulting (Compugen). Through portal developments and improvements in
internet transparency, researchers can access tools and search algorithms, data-
bases, patent and scientific literature, news, and jobs listings (Thayer, 2000).
A third type of company that arose supports the R&D process through the
development of tools for analysis. Examples are the producers of genechips of
which Affymetrix is one example.
Lastly and of particular interest to our argument, a few companies have
emerged focused at the integration of various parts of the information and
planning environment of R&D. Spotfire, for instance, delivers planning and
integration software that allows access to the information space and uses
software to integrate and display the findings in a specific way. Thus organiza-
tion of the research process such as planning, reporting and access to ongoing
results has been developed as a specific set of tools.
The way in which the different levels—discovery environment, R&D collabo-
ration, and corporate collaboration represent opportunities can be discussed on
the basis of recent developments in the sector of genomic companies. When we
look at the fate of the 15 companies presented in Table 1, it is clear that in the
last years new patterns have emerged.
Underlying this emergence of new businesses is the need to integrate increasing
amounts of data and information available on chemical, genetic and disease
information. This increase has shifted the approach in pharmaceutical research
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from a lack of information to an overload of information on many relevant
aspects. Both internal and external information sources have grown in volume
and the presentation and integration of the information has become a crucial
point. The surplus availability and combination of data is therefore a bottleneck
in the quest for new active compounds. The approach many companies take is
to shield proprietary parts of this information process. On the other hand, in
order to access data sources of other companies and actors the field also has
some characteristic of the field of software development. In this field an
important though not uncontested premise is the strategic use of standards and
open source software. In order to combine the information retrieved from
databases and research these two aspects need to be combined.
It thus seems that these two fields are basic as starting elements for infor-
mation centred innovation systems. In part these fields have become central,
because of the necessity to integrate large amounts of diverse information that
have become available. Drug research is ‘data rich put information poor’
(Thayer, 2000). The drug discovery process is reshaped by these changes. The
manner in which these changes will affect the structure of the industry is
however less clear. Fundamental differences of opinion exist between new
companies as to what will constitute a viable long-term model. Initially, it was
expected that data and information selling would be a viable business model in
itself (Howard, 2000; Haussler, 2001). There was however also early scepticism,
which claimed that pure information providers and brokers would not survive
(Jones, 2000). Increasingly these functions indeed have come under pressure as
the large pharmaceutical companies cut back on their spending and publicly
available databases of genetic information emerged. Presently, a number of the
companies in Table 1 are restructuring and some are trying to become drug
developers themselves. It seems increasingly unlikely that information storing
and manipulating as routine as a business model will survive. Software on
decoding rearranging and interpretation still seems viable but rather marginal.
Tool production as well as ERP like support for the R&D process still seems to
be strong.
Some new companies, including for example US based Millennium, are
hesitant to become involved in networking based on new information processes
with large pharmaceutical companies and aim at building an integrated genom-
ics based drug development capacity. Thus they may represent a new wave of
emerging companies with innovation as its core and not so much centered on
the new opportunities driven by. Andersen Consulting discusses the changes of
large pharmaceutical companies that go in the opposite direction (Accenture,
2001). The authors claim that Web-enabled networks will further ‘virtualize’
R&D activities binding the partners’ capabilities without regard to company
borders (Accenture, 2001). The crucial bottleneck is the discovery of new drugs.
The traditional screening methods fail to come up with sufficient numbers
of new compounds. It is hoped that genomic information and work by other
companies will help to tackle this. The use of ICT is also expected to increase
access to scarce human expertise and knowledge, among others by the
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proliferation of internet-based clinical networks. In such networks patient
groups, medical specialists and pharmaceutical companies are expected to work
together. According to the Andersen report, in this process disease oriented web
communities and therapy specific sites could form dual structures for testing
and information exchange. The main claim of the Andersen report is that
existing large companies may evolve to backbones for networks organizing
information, therefore directing in the same direction (also at the high point of
e-business optimism) as new emerging businesses were thought to have taken.
Mediating institutional research networks—a research agenda
Genomics has become an important field for social scientists and humanities
researchers. The main focus is, however, often the ethical dimension and the
exploration of possible societal consequences of the new genomics initiatives. In
this section, we will argue that there is a need for studies with an additional
focus. Limiting the spectrum of social studies of genomics to ethics and
consequences of genomics not only runs the risk of missing important analytical
dimensions of genomics and related phenomena, it also increases the danger
that social scientific and humanities research will be ‘frozen’ in an instrumental
mode, either in favour of or opposed to the further development of genomics
research and applications. An effort to map the role of information and
communication technologies in the development of genomics is needed, to
better understand the dynamics of genomics both as a socio-technical field of
knowledge creation and as a field of making society.
This approach builds further upon work in science studies and the history of
science that has analysed the turn to informational research in the life sciences.
Lily Kay (2000) concludes that genomics is ‘moving beyond monogenetic and
polygenetic determinism, even beyond functional genomics, toward a phase
concerned with nonlinear, adaptive properties of complex dynamic systems,
where visions of linear causality would be replaced by analyses of networks
interacting with the environment and operating across levels of regulations:
genetic, epigenetic, morphogenetic, and organismal’. The transformation of the
life sciences into information sciences (Lenoir, 1999) makes information the
essence of life. ‘Genomic biopower promises new levels of control over life
through the pristine metalevel of information: through control of the word, or
the DNA sequence’ (Kay, 2000). She therefore sees her study of the history of
the book of life as a study of ‘an epistemic rupture from purely material and
energetic to an informational view of nature and society’. The latter is not given
by nature but the product of historical contingency. It was not so much the
mathematical content of information science that shaped the new agenda in the
life sciences, contrary to predictions by many leaders of the informational
revolution in the late 1940s, but the discourse about information. ‘Information,
partly displacing the concept of specificity, became a guiding metaphor, or
rather a metaphor of a metaphor, in molecular biology and in the work on the
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genetic code’ (Kay, 2000). She concludes that ‘genomic textuality’ has become
a fact of life and commercial futures.
The informatisation has direct implications for all three levels at which
genomics can be analysed. Already in 1991, Victor McKusick concluded that a
new breed of scientist was being created in the genomics laboratories, ‘one who
is prepared to capitalize on both the molecular genetics revolution and the
computation revolution. These will be the leaders in biology in the 21st century’
(McKusick, 1991). The importance and steering influence of information
infrastructures has been analysed by Bowker and Star (1999). Classification is
not an innocent activity. The same holds for information infrastructures in
general. ‘Seemingly purely technical issues like how to name things and how to
store data in fact constitute much of what we have come to know as natural’
(Bowker & Star, 1999). This approach has been used by Mackenzie to propose
two main ways to analyse the circulation of genetic sequences in bioinformatics
practice (Mackenzie, 2003). One would be the analysis of the character of
bioinformatics software and algorithms. The second approach would be the
analysis of practices, ‘the different ways that biologists, institutions and corpora-
tions retrieve and organise sequence data’. The latter would lead to an under-
standing of the ways in which different sets of potential determinations of living
bodies are generated within an organisational milieu. This directly affects both
the logic of research and the commercial and political relationships in which
genomic objects are embedded and that they create. An example of the first type
of implication is the invention of the improved robot scientist in the field of
functional genomics (King et al., 2004). As noted above, this robot is able to
originate hypotheses to explain observations, devise experiments to test these
hypotheses, physically run the experiments using another robot, interpret the
results to falsify hypotheses inconsistent with the data, and to repeat this cycle.
What Leroy Hood (2002) has coined ‘discovery science’ is clearly not a
complete break with hypothesis driven research but extends the use of hypoth-
eses by modelling them computationally. The potential of the robot scientist is
not seen by its creators as a complete replacement of human creativity. Rather
the expectation is that repetitive chores can be done by robots, thereby freeing
the scientists ‘to make the high-level creative leaps at which they excel’. The
commercial and political aspects are important in that the new genomics
databases and software tools shed light on ‘how biological corporealization and
the generation of new forms of property and innovation mutually contextualise
themselves through movements of data, and in particular, through movements
of data modulated by enterprise property relations’ (Mackenzie, 2003).
Genomics research is deeply embedded in complex socio-technical
configurations. ICT tools and configurations play a crucial role in the develop-
ment of the field itself as well as in the interaction between genomics and
society. A direct connection between the development of ICT infrastructure and
the application of genomic information in research is used by the pharmaceuti-
cal industry for innovation purposes. In the previous section we introduced
alternative models in which the pharmaceutical industry is rather depicted as a
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key organizer of health-related R&D activities, integrating genetic and other
basic scientific information with health related information and health system
and patient related information. In this open claim for an orchestrating role for
this sector, it seems to us that also a different route is visible which starts with
the need to integrate knowledge, plan research and seizing of opportunities. One
direction that has been taken is the assemblage of the various knowledge
elements through entrepreneurial activity. The resulting knowledge network
changes the conditions for the existing corporate R&D structures. In between
university science, large corporate laboratories the new start-up genomics com-
panies emerge. In other words, the innovation processes are mediated by these
networks. The role of ICT is both enabling for and constrained by these
networks.
To summarize, the development of bioinformatics, enabled by internet medi-
ation, is driving new strategies of life science research. As an example of a
specific segment of players in this area, we discussed the literature with respect
to the consequences of virtualisation at three levels, with the pharmaceutical
industry as an example. One set of arguments concerned with these develop-
ments claims that they will result in a significant reorientation and strengthening
of R&D capabilities. In line with these arguments, we can point to the
emergence of companies focusing on process integration, enabling research
planning and integration of available resources. Whether these companies will
continue to develop as independent enterprises or as parts of big companies
remains, however, an open question.
These strategies are embedded in an overall process that can be called
informatisation or, more specifically, the informational turn in research
(Wouters et al., 2002a; Beaulieu, 2004). To grasp these developments and their
impact on the niches for research strategies, it is therefore necessary to go
beyond descriptive case studies of use of ICT in specific research and corporate
settings. An analysis of the interaction between different levels of ICT use is
needed. We have moreover concluded that rather than emerging as seamless,
the networks retain specific structural characteristics. The role of specific elements
of these networks in the dynamics of the interaction between ICT and genomics
research and product development therefore becomes of crucial interest. We
have characterised four different types of corporate research strategies in the
literature. The effects and viabilities of these strategies as well as their effects on
other users (such as patient groups) merits further study, especially with an eye
to the mediating and (re)presentational role of ICT. An interesting aspect is
here the balance between proprietary and public information spaces.
We propose that research should address the characterization and analysis of
these dynamics at three different but interrelated levels: the level of research
practice; the level of research communication and inter-group collaboration, and
the level of global, institutional networks of public, academic and commercial
organizations. At the first level of research practices, the workbench as it were,
the role of specific elements in networks of innovation seems especially interest-
ing. Important research questions seem to be going beyond the notion of the
D
o
w
n
lo
ad
ed
 B
y:
 [
Vr
ij
e 
Un
iv
er
si
te
it
, 
Li
br
ar
y]
 A
t:
 1
5:
42
 3
1 
Ma
y 
20
11
182 Peter Groenewegen & Paul Wouters
seamless web. In this regard, the characteristics of data flows (Arzberger et al.,
2004) and the balance between old and new knowledge may be interesting. At
the second level of research communication and inter-group collaboration, the
characteristics of inter-group networks, both in terms of structure and of
process, seem especially interesting. The increased use of computer networks in
communication among researchers has led to high expectations regarding ‘vir-
tual research institutes’. Such virtual institutes are presently being promoted by
science policy (both at the national, European and international level) because
they are expected to accelerate the process of knowledge creation. These virtual
institutes are more than just the replacement of existing institutes into cy-
berspace. They combine functions that were previously assigned to separate
social institutions, such as the library, the post office, the teleconference and the
faculty. And they are built around technology that may add a new dynamic to
their development. This brings to the fore questions about the influence of
institutional arrangements on research practices and the way ICT affects the
balance between cooperation and competition. At the third level of of global,
institutional networks of public, academic and commercial organizations, the
notion of niche for innovation seems especially interesting. Innovative opportu-
nities are recognized and acted on by interdependent social actors from the
private and public sector. The relations between new biotechnology firms,
existing chemical and pharmaceutical companies, and universities can be ana-
lyzed as opportunity networks. Network positions influence access to resources
recognition of opportunities that occur, and play a role in acquiring legitimacy
(Baum et al., 2000). The effects of government-led actions will be enhanced or
hampered by the interaction with actions already independently undertaken by
large companies, banks and venture capitalists. Therefore public resources are
converted into innovation by research organisations, as well as firms (Coriat &
Weinstein, 2002). Information flow and thematic focus of such networks can
help to estimate the potential to exploit specific knowledge gathered/distributed
in virtual research organisations. Such networks for applications in social
domains need to be part of larger communities requiring balancing between
public and private interests. The legitimacy of the efforts of various partners is
not a priori given: it needs to be earned and secured. Relevant is the discussion
on expertise on the balance between regulation aimed at risk assessment and
innovation (Morris, 2000). This leads to questions about the role of specific
innovation networks in genomics and the balance between the private and the
public sector.
This analysis will need to draw on the sociology of knowledge, the study of
the internet, and innovation network studies. The use and subsequent further
development of information and communication technologies in the life sciences
has consequences that reach further than the immediate instrumental aspects in
the laboratory and development of data networks. They also shape the interface
between genomic research and society at large. ICTs are not only configured by
the user, they also ‘configure the user’ directly and indirectly (Woolgar, 2002).
Therefore, it is crucial that the socio-technical interactions in the present
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take-off of genomics and bio-informatics research are analyzed. This is the more
so because the use of ICTs varies by scientific field (Walsh & Bayma, 1996).
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